Trait Biosciences' CBD82S Demonstrates Enhanced Skin and Intestinal Permeation

Trait Biosciences has announced significant advancements in the delivery and transport of its cannabinoid product, CBD82S™. The company’s research, conducted in ex vivo models, has shown that CBD82S™ outperforms conventional CBD in terms of membrane permeation and transport. Specifically, CBD82S™ demonstrated over 100-fold greater skin permeation compared to conventional CBD under the tested conditions. This finding is particularly noteworthy given the challenges associated with the delivery of conventional CBD, which is naturally lipophilic and water-insoluble.

In addition to enhanced skin permeation, CBD82S™ also showed improved transport across the intestinal membrane. These results suggest that CBD82S™ behaves differently from conventional CBD in various biological barriers, potentially opening new avenues for its application in both topical and oral delivery systems.

The importance of membrane permeation cannot be overstated. For topical applications, skin permeation is crucial for the compound to reach relevant skin layers. For oral delivery, the intestinal membrane is a key barrier that influences the absorption of the compound into the systemic circulation. The enhanced permeation and transport properties of CBD82S™ could make it a more effective and efficient option for both forms of delivery.

In a related study, CBD82S™ also demonstrated an approximately 25-fold longer apparent half-life in a human liver microsome model compared to conventional CBD. This finding adds to the understanding of how CBD82S™ behaves in different biological models and supports the company's ongoing research into the mechanisms underlying its unique properties.

While these ex vivo findings are promising, Trait Biosciences emphasizes that further research is needed to fully understand the molecular mechanisms responsible for the differences observed between CBD82S™ and conventional CBD. The company continues to conduct studies to evaluate the absorption, systemic exposure, and pharmacokinetic performance of CBD82S™.

The results of these studies underscore the potential of CBD82S™ in overcoming the formulation and delivery challenges associated with conventional CBD. The company's proprietary technology platform has enabled the development of a water-soluble cannabinoid molecule with distinct physicochemical properties, which could have significant implications for the future of cannabinoid research and application.

These findings add to Trait Biosciences' broader research efforts and provide a basis for investigating how the unique properties of CBD82S™ may influence its delivery and potential biological activity. The company remains committed to advancing the understanding and application of cannabinoid science through rigorous scientific inquiry and innovation.